AI Insight
A phase 3 clinical trial published in The Lancet demonstrates that cagrilintide-semaglutide combination therapy significantly reduces HbA1c levels in type 2 diabetes patients already using basal insulin. The dual-drug treatment at doses of 2.4 mg and 1.0 mg achieved statistically significant improvements in blood sugar control compared to placebo, while also producing substantial weight loss without increasing hypoglycemia risk. The safety profile remained consistent with known side effects of GLP-1 receptor agonists and previous cagrilintide data.
Why it matters
This combination therapy offers a new treatment option for type 2 diabetes patients who have inadequate glycemic control with basal insulin alone, potentially improving disease management without the common complication of low blood sugar. The dual benefit of improved glucose control and weight reduction addresses two critical aspects of type 2 diabetes management simultaneously.
Understand the Science
Cagrilintide–semaglutide at doses of 2·4 mg each and 1·0 mg each met the primary endpoint, with statistically significant and clinically relevant HbA1c reductions versus placebo when added to basal insulin-treated type 2 diabetes. These reductions were accompanied by robust bodyweight reduction and no additional risk of hypoglycaemia. The safety profile was consistent with that of the GLP-1 receptor agonist class and previous safety data for cagrilintide. Findings support the use of cagrilintide–semaglutide as an add-on to once per day basal insulin to significantly improve glycaemic control.